Skip to main content

Drug Interactions between lesinurad and pegloticase

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

pegloticase lesinurad

Applies to: pegloticase and lesinurad

GENERALLY AVOID: Concomitant use of oral urate-lowering therapy and pegloticase may potentially blunt the rise of serum uric acid levels, which may make it difficult to assess patient risk for anaphylaxis and infusion reactions. The risk for both is higher in patients whose uric acid level increases to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed. Therefore, serum uric acid levels should be monitored prior to infusions of pegloticase, and treatment discontinuation considered if levels increase to above 6 mg/dL.

MANAGEMENT: Oral urate-lowering medications should be discontinued prior to initiation of pegloticase and not used during pegloticase treatment.

References (1)
  1. (2010) "Product Information. Krystexxa (pegloticase)." Savient Pharmaceuticals

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer